Cancer vaccine composed of PRM1 epitope may facilitate tumor control by induction of specific immune response, since we have demonstrated that anti-PRM1 can be used as an antagonist of secreted PRM1 to inhibit CRC tumorigenesis and cell proliferation. Here, PRM1 is linked to cancer.